Hereditary Periodic Fever Syndrome (TRAPS)

Comprehensive Clinical Guide: Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)

1. Introduction and Clinical Overview

Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), formerly known as Familial Hibernian Fever, is a rare, autosomal dominant autoinflammatory disorder. It belongs to the family of periodic fever syndromes, characterized by recurrent episodes of systemic inflammation without evidence of high-titer autoantibodies or antigen-specific T-cell activation.

Unlike autoimmune diseases, which involve the adaptive immune system, TRAPS is a disorder of the innate immune system. It was first identified in a family of Irish-Scottish descent, but it has since been documented in diverse ethnic populations worldwide. The hallmark of the disease is the prolonged duration of febrile episodes compared to other autoinflammatory conditions like Familial Mediterranean Fever (FMF).

2. Etiology and Pathophysiology

The pathophysiology of TRAPS is rooted in mutations of the TNFRSF1A gene, which encodes the 55-kDa TNF receptor (TNFR1).

Molecular Mechanisms

• Gene Mutation: Mutations in TNFRSF1A are almost exclusively missense mutations that lead to the misfolding of the TNFR1 protein.
• Protein Misfolding: The mutant protein becomes trapped within the endoplasmic reticulum (ER), triggering an Unfolded Protein Response (UPR) and subsequent ER stress.
• Dysregulated Signaling: The failure of the receptor to properly shed from the cell surface or the abnormal intracellular accumulation leads to an exaggerated inflammatory response.
• Cytokine Cascade: This results in the excessive release of pro-inflammatory cytokines, primarily Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α).

Genetic Inheritance

TRAPS follows an autosomal dominant pattern of inheritance with variable penetrance. While most cases are familial, de novo mutations have been reported. Genetic counseling is paramount for affected families to assess the risk of transmission to offspring.

3. Clinical Presentation and Staging

TRAPS is clinically heterogeneous, ranging from mild, infrequent episodes to severe, chronic inflammatory states.

Standard Presentation

1. Fever: Episodes typically last 1 to 3 weeks, significantly longer than the 1–3 day duration seen in FMF.
2. Myalgia: Often intense and migratory, frequently localized to the extremities.
3. Rash: Usually maculopapular, erythematous, and migratory. It is often painful and may be accompanied by overlying edema.
4. Ocular Involvement: Periorbital edema is a pathognomonic feature of TRAPS, occurring in a significant subset of patients.
5. Serositis: Abdominal pain, pleurisy, and chest pain are common due to inflammation of the serosal membranes.
6. Arthralgia/Arthritis: Usually oligoarticular and non-erosive.

Clinical Grading

While there is no universally standardized staging system, clinicians often categorize TRAPS based on the frequency and severity of flares:
* Mild: Infrequent flares (1–2 per year) with minimal constitutional symptoms.
* Moderate: Episodic flares (3–6 per year) requiring intermittent NSAIDs or short-course corticosteroids.
* Severe: Frequent or chronic, smoldering inflammation, often requiring long-term biological therapy to prevent complications like Amyloidosis.

4. Diagnostic Approach

Diagnosis is clinical, supported by laboratory findings and confirmed by genetic testing.

Key Diagnostic Tests

Differential Diagnosis

It is essential to distinguish TRAPS from other periodic fever syndromes:
* Familial Mediterranean Fever (FMF): Shorter fever duration, presence of MEFV gene mutations.
* Mevalonate Kinase Deficiency (MKD/HIDS): Associated with elevated mevalonic acid in urine and mevalonate kinase deficiency.
* PFAPA Syndrome: Typically pediatric; "Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis."
* Cryopyrin-Associated Periodic Syndromes (CAPS): Triggered by cold; NLRP3 mutations.

5. Risks and Complications

The most severe, life-threatening complication of TRAPS is Secondary (AA) Amyloidosis.

• Mechanism: Chronic, uncontrolled systemic inflammation leads to the deposition of serum amyloid A protein in vital organs, particularly the kidneys.
• Clinical Impact: Renal failure is the primary cause of morbidity and mortality in long-standing, untreated, or undertreated TRAPS patients.
• Other Risks:
  • Growth retardation in pediatric patients due to chronic inflammation.
  • Psychosocial impact of chronic, unpredictable illness.
  • Side effects of long-term immunosuppressive therapy (e.g., opportunistic infections).

6. Management and Therapeutic Strategies

Treatment has evolved from symptom management to targeted biologic therapy.

1. NSAIDs: Used for acute, mild flares to control pain and inflammation.
2. Corticosteroids: Highly effective for acute flares but should be used with caution due to the risk of rebound and long-term side effects.
3. IL-1 Inhibitors (e.g., Canakinumab, Anakinra): Currently the preferred treatment for frequent or severe TRAPS. These target the downstream cytokine cascade.
4. TNF Inhibitors (e.g., Etanercept): Historically used, though efficacy is variable; some patients may experience a paradoxical worsening of symptoms.

7. Frequently Asked Questions (FAQ)

1. Is TRAPS curable?
Currently, there is no cure for TRAPS. It is a lifelong genetic condition. However, with modern biologic therapies, most patients can achieve complete remission and lead normal lives.

2. How long do TRAPS episodes last?
Unlike FMF, which lasts 1–3 days, TRAPS episodes typically last between 1 to 3 weeks.

3. Is periorbital edema specific to TRAPS?
Yes, periorbital edema (swelling around the eyes) is highly suggestive of TRAPS and is a key clinical differentiator from other periodic fevers.

4. What is the biggest danger of having TRAPS?
The most significant long-term risk is the development of AA amyloidosis, which can lead to kidney failure. Strict control of inflammation is necessary to prevent this.

5. Can TRAPS be diagnosed without genetic testing?
While the clinical presentation is suggestive, genetic testing of the TNFRSF1A gene is required for a definitive diagnosis.

6. Does the fever always occur in TRAPS?
Usually, yes. However, some patients may experience "smoldering" inflammation where they have elevated inflammatory markers without a classic spike in temperature.

7. Is surgery ever required for TRAPS?
Surgery is rarely indicated. In cases of severe, irreversible kidney damage due to amyloidosis, a renal transplant may be necessary.

8. Are there specific triggers for a TRAPS flare?
Triggers can include physical trauma, infection, stress, or sometimes no identifiable trigger at all.

9. How is TRAPS inherited?
It is inherited in an autosomal dominant manner. An affected parent has a 50% chance of passing the mutation to each child.

10. Can I have a normal life with TRAPS?
Yes. With early diagnosis, regular monitoring of inflammatory markers (like SAA), and appropriate biologic therapy, patients typically have a normal life expectancy and quality of life.

8. Prognosis and Long-term Monitoring

The prognosis for TRAPS is generally favorable if the patient is under the care of a rheumatologist specializing in autoinflammatory diseases.

Monitoring Requirements:

• Routine Bloodwork: Monitoring of CRP, SAA, and renal function (urinalysis for proteinuria) every 3–6 months.
• Biologic Monitoring: Regular evaluation for signs of infection, especially when using IL-1 or TNF inhibitors.
• Multidisciplinary Care: Coordination between rheumatology, nephrology (for amyloidosis screening), and clinical genetics.

Conclusion

TRAPS represents a complex intersection of protein misfolding, ER stress, and innate immune dysregulation. As our understanding of the TNFRSF1A pathway deepens, therapeutic options continue to shift toward highly specific cytokine blockade. The clinical focus must remain on the early identification of patients at risk for amyloidosis and the aggressive suppression of systemic inflammation to ensure long-term organ preservation and quality of life. Clinicians should maintain a high index of suspicion for patients presenting with prolonged febrile episodes, migratory rashes, and periorbital edema, particularly when a family history of autoinflammatory conditions exists.